An expert panel in the United States has recently voted against the use of MDMA therapy for treating post-traumatic stress disorder (PTSD), dealing a blow to the potential use of the party drug for therapeutic purposes. MDMA, also known as ecstasy or molly, has been considered for its therapeutic benefits in treating certain mental health conditions.

The panel of advisers to the Food and Drug Administration (FDA) voted 10-1 against the overall benefits of using MDMA to treat PTSD, citing concerns about the effectiveness of the drug based on available data. Out of the 11 panel members, nine expressed doubts about the drug’s efficacy in PTSD patients.

The decision came after a review of research conducted by drugmaker Lykos Therapeutics, which recommended combining the treatment with talk therapy sessions led by a licensed mental health provider. One of the trials revealed that 71% of the participants in the treatment group no longer met the criteria for PTSD, compared to 48% in the placebo group.

However, panelists raised several issues regarding the data, including doubts about the long-term benefits of the treatment, concerns about the study designs, and potential risks such as heart problems, injuries, and abuse. Dr. Melissa Decker Barone, a psychologist with the Department of Veterans Affairs, highlighted the numerous questions surrounding the effectiveness of the treatment.

While the FDA is not bound to follow the panel’s recommendations, it typically considers the feedback provided. A final decision on the matter is anticipated by August 11. In a separate development, Australia’s regulatory authority recently approved the use of drugs, including MDMA, to support therapy sessions, marking a significant step in the treatment of PTSD.